- This event has passed.
AstraZeneca’s 2 Million Genomes Initiative
Genomics currently is the most powerful tool to elucidate the cause and complexity of diseases. Critical for novel target identifications, better understanding of disease biology, and patient’s stratification on clinical trials. In April 2016, AstraZeneca launched the genomics initiative aim to reap benefits from the goal of sequencing up to 2 million genomes. In a longer-term to transform drug discovery and development across R & D pipeline. The thinking behind the strategy and the progress and development to-date will be discussed.REGISTER NOW